Replies to post #367517 on Amarin Corp Plc (AMRN)

[Number sleven]

LTRO, That would not be a bad thing. One more reason to look forward to April. The older I get, the less I like winter.
Sleven,

[Whalatane]

My take is they will have enough data before April 3 to know if Vascepa provides at least 15% RRR in various Covid endpts in the population studied.

Look at the case rate dated Jan 25th in their key recruiting county
https://sac-epidemiology.maps.arcgis.com/apps/MapSeries/index.html?appid=e11bc926165742ab99f834079f618dad

Its important to get this info as soon as possible as many of these Kaiser patients in this trial profile know the efficacy of their 3rd Covid shot ( the booster ) and the original shots .....has probably worn off.

So come April we know our Covid shots have lost most of their protection .
Whats next before the next variant or the expected winter re emergence ?

IF Vascepa reduces hospitalization , need for urgent care etc by at least 15% with a stat significance P value of .01 or better ....I expect Kaiser to prescribe / offer Vascepa to all their patients that meet the MITIGATE profile

Kiwi